Cancer Network Editors | Authors


FDA Approves CAR T-Cell Therapy Idecabtagene Vicleucel for Previously Treated Multiple Myeloma

March 27, 2021

The approval of idecabtagene vicleucel was supported by results from the phase 2 KarMMa trial, which evaluated the safety and efficacy of idecabtagene vicleucel (ide-cel) in patients who had received at least 3 prior regimens and were refractory to their last regimen per IMWG criteria.

Higher OS With Neoadjuvant Chemo-RT in Pancreatic Cancer

June 19, 2018

In PREOPANC, the 2-year survival rate was significantly higher for patients who received neoadjuvant chemoradiotherapy vs standard care.

New Role for Maintenance Chemo in Rhabdomyosarcoma?

June 14, 2018

Six months of maintenance chemotherapy improved OS in children with high-risk rhabdomyosarcoma.

Should mFOLFIRINOX Be Standard of Care in Adjuvant Tx of Pancreatic Cancer?

June 14, 2018

Compared with gemcitabine, mFOLFIRINOX improved outcomes for all endpoints when used in the adjuvant setting.

Quiz: Are Antidepressants Linked With Increased Ovarian Cancer Risk?

February 15, 2018

Do you know how many new cases of ovarian cancer are expected in 2018? And could long-term oral contraceptive use be a chemopreventive for certain gynecologic cancers? Test your knowledge in our latest quiz.

Quiz: What Newly Approved Drug Treats Bone Metastases in Multiple Myeloma?

February 15, 2018

Do you know what dose of carfilzomib is associated with an increased incidence of cardiovascular events in multiple myeloma patients? How about the estimated incidence of new myeloma cases in 2018? Test your knowledge in our latest quiz.

Oncology Pulse Survey Results

January 15, 2018

Last month we asked our readers: If you were to start your career again, would you still choose oncology, would you pick a different specialty, or would you perhaps not choose a career in medicine at all? Here are the results.

Top Lung Cancer News of 2017

December 20, 2017

In this slide show we highlight some of the top news on lung cancer in 2017, including FDA approvals, a new standard of care for ALK-positive lung cancer, increased risk with vitamin B supplements, and more.